Eli M. Roth
About
Eli M. Roth is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Eli M. Roth has authored 60 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Surgery, 17 papers in Endocrinology, Diabetes and Metabolism and 16 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Eli M. Roth's work include Lipoproteins and Cardiovascular Health (41 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers). Eli M. Roth is often cited by papers focused on Lipoproteins and Cardiovascular Health (41 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers). Eli M. Roth collaborates with scholars based in United States, France and United Kingdom. Eli M. Roth's co-authors include James M. McKenney, Evan A. Stein, Corinne Hanotin, Gaëlle Asset, Dirk Blom, Maria Laura Monsalvo, Scott M. Wasserman, Robert C. Scott, Christie M. Ballantyne and Michael J. Koren and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.
In The Last Decade
Eli M. Roth
58 papers receiving 2.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Eli M. Roth United States | 24 | 2.1k | 781 | 587 | 586 | 326 | 60 | 2.7k | ||
| Norman E. Lepor United States | 8 | 1.8k 0.8× | 656 0.8× | 473 0.8× | 460 0.8× | 291 0.9× | 13 | 2.4k | ||
| Ton Oude Ophuis United States | 12 | 2.6k 1.2× | 935 1.2× | 1.1k 1.8× | 1.2k 2.0× | 289 0.9× | 21 | 3.4k | ||
| Armando Lira Pineda United States | 13 | 2.3k 1.1× | 594 0.8× | 731 1.2× | 800 1.4× | 420 1.3× | 21 | 2.8k | ||
| Ransi Somaratne United States | 15 | 3.0k 1.4× | 1.1k 1.4× | 705 1.2× | 597 1.0× | 478 1.5× | 25 | 3.3k | ||
| Joanne Palmisano United States | 19 | 1.9k 0.9× | 661 0.8× | 805 1.4× | 652 1.1× | 95 0.3× | 30 | 2.6k | ||
| William J. Sasiela United States | 21 | 2.9k 1.4× | 528 0.7× | 1.0k 1.7× | 1.2k 2.0× | 694 2.1× | 61 | 3.9k | ||
| Lorenzo Melani Italy | 19 | 1.7k 0.8× | 530 0.7× | 554 0.9× | 448 0.8× | 166 0.5× | 28 | 2.3k | ||
| Ricardo Dent United States | 20 | 1.6k 0.8× | 684 0.9× | 343 0.6× | 296 0.5× | 209 0.6× | 41 | 2.0k | ||
| G. Kees Hovingh Netherlands | 30 | 2.1k 1.0× | 307 0.4× | 1.3k 2.1× | 1.0k 1.7× | 284 0.9× | 76 | 3.4k | ||
| Traci Turner United States | 12 | 1.8k 0.9× | 568 0.7× | 487 0.8× | 478 0.8× | 320 1.0× | 39 | 2.4k |
Countries citing papers authored by Eli M. Roth
Since
Specialization
Citations
This map shows the geographic impact of Eli M. Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli M. Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli M. Roth more than expected).
Fields of papers citing papers by Eli M. Roth
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eli M. Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli M. Roth. The network helps show where Eli M. Roth may publish in the future.
Co-authorship network of co-authors of Eli M. Roth
This figure shows the co-authorship network connecting the top 25 collaborators of Eli M. Roth. A scholar is included among the top collaborators of Eli M. Roth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli M. Roth. Eli M. Roth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Robinson, Jennifer G., Michel Farnier, John J.P. Kastelein, et al.. (2019). Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. Journal of clinical lipidology. 13(6). 979–988.e10.
2.
Roth, Eli M., Anne C. Goldberg, Alberico L. Catapano, et al.. (2016). IMPACT OF ANTI-DRUG ANTIBODIES TO ALIROCUMAB ON LDL-C LOWERING EFFICACY AND SAFETY. Journal of the American College of Cardiology. 67(13). 1863–1863.
3.
Tóth, Peter P., Sara Hamon, Steven R. Jones, et al.. (2016). Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids in Health and Disease. 15(1). 28–28.
4.
Blom, Dirk, Maria Laura Monsalvo, Kate Tsirtsonis, et al.. (2015). EFFECTS OF EVOLOCUMAB (AMG 145) TREATMENT ON VITAMIN E LEVELS: RESULTS FROM THE 52-WEEK PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED DESCARTES STUDY. Journal of the American College of Cardiology. 65(10). A1367–A1367.
5.
Koren, Michael J., Eli M. Roth, James M. McKenney, et al.. (2015). Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgraduate Medicine. 127(2). 125–132.
6.
Emami, Hamed, Esad Vucic, Sharath Subramanian, et al.. (2015). The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial. Atherosclerosis. 240(2). 490–496.
7.
Dunbar, Richard L., Stephen J. Nicholls, Kevin C. Maki, et al.. (2015). Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids in Health and Disease. 14(1). 98–98.
8.
Roth, Eli M., Maja Bujas‐Bobanovic, Michael J. Louie, & Bertrand Cariou. (2015). Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. Clinical Therapeutics. 37(9). 1945–1954.e6.
9.
Gaudet, Daniel, Dean J. Kereiakes, James M. McKenney, et al.. (2014). Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials). The American Journal of Cardiology. 114(5). 711–715.
10.
Roth, Eli M., Marja‐Riitta Taskinen, Henry N. Ginsberg, et al.. (2014). A 24-WEEK STUDY OF ALIROCUMAB AS MONOTHERAPY VERSUS EZETIMIBE: THE FIRST PHASE 3 DATA OF A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR. Journal of the American College of Cardiology. 63(12). A1370–A1370.
11.
Moriarty, Patrick M., Eli M. Roth, Adam Karns, et al.. (2014). Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study. Journal of clinical lipidology. 8(6). 568–575.
12.
Maki, Kevin C., David G. Orloff, Stephen J. Nicholls, et al.. (2013). A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). Clinical Therapeutics. 35(9). 1400–1411.e3.
13.
Gaudet, Daniel, Dean J. Kereiakes, Eli M. Roth, et al.. (2012). Abstract 14725: Effect of SAR236553/REGN727 Fully Human Monoclonal Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody on Plasma Lipoprotein(a) Concentrations: Pooled Analysis from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443). Circulation. 126.
14.
Roth, Eli M., James McKenney, Corinne Hanotin, Gaëlle Asset, & Evan A. Stein. (2012). THE EFFECTS OF CO-ADMINISTERING A MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SERINE PROTEASE, REGN727/SAR236553, WITH 10 AND 80 MG ATORVASTATIN COMPARED TO 80 MG ATORVASTATIN ALONE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (NCT: 01288469). Journal of the American College of Cardiology. 59(13). E1620–E1620.
15.
Roth, Eli M., Robert S. Rosenson, Peter H. Jones, et al.. (2012). Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies. Journal of clinical lipidology. 6(6). 534–544.
16.
Roth, Eli M., Robert S. Rosenson, Dawn M. Carlson, et al.. (2010). Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study. Cardiovascular Drugs and Therapy. 24(5-6). 421–428.
17.
Kipnes, Mark, Eli M. Roth, Carolyn M. Setze, et al.. (2009). Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination. Clinical Drug Investigation. 30(1). 51–61.
18.
Dean, Larry S., Thomas M. Broderick, Eli M. Roth, et al.. (2000). Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes. American Heart Journal. 139(2). s53–s60.
19.
Dean, Larry S., et al.. (1999). Efficacy of Abciximab Induced Platelet Blockade Using a Rapid Point of Care Assay. Journal of Thrombosis and Thrombolysis. 7(3). 265–276.
20.
Ellendorff, F., Eli M. Roth, & Diedrich Smidt. (1970). THE INFLUENCE OF FSH, LH AND TESTOSTERONE ON THE SEXUAL BEHAVIOUR AND TESTICULAR FUNCTION OF THE BOAR. Reproduction. 21(2). 347–352.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Norman E. Lepor Breakdown of academic impact, for papers by Ton Oude Ophuis Breakdown of academic impact, for papers by Armando Lira Pineda Breakdown of academic impact, for papers by Ransi Somaratne Breakdown of academic impact, for papers by Joanne Palmisano Breakdown of academic impact, for papers by William J. Sasiela Breakdown of academic impact, for papers by Lorenzo Melani Breakdown of academic impact, for papers by Ricardo Dent Breakdown of academic impact, for papers by G. Kees Hovingh Breakdown of academic impact, for papers by Traci Turner